RayKnowChina Research Map
Shortlist

Cancer

Breast cancer in Changchun

长春 乳腺癌

All diseases in Changchun

4 hospitals in Changchun

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Changchun may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 77 papers led
  2. 51 papers led
    No open trial led
  3. 20 papers led
    No open trial led
  4. 2 papers led
    No open trial led

Breast cancer in every city Changchun on the disease page, with the national map

40

open trials on breast cancer with a hospital in Changchun

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Changchun as lead sponsor or study site. 2 of them are led by a hospital in Changchun. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT06993506

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou

  2. Recruiting
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07281976

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou

  3. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  4. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  5. Recruiting
    A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06738966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Jinan

  6. Recruiting
    A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06827236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBengbu, Changchun, Chengdu, Chongqing, Nanning, Shanghai, Xi'an

  7. Recruiting
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06841354

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  8. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  9. Recruiting
    The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06995118

    Age 18 years to 70 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Nanchang, Zhengzhou

  10. Recruiting
    A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07003074

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan

  11. Recruiting
    Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07008976

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou

  12. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  13. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  14. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  15. Recruiting
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07060807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou

  16. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  17. Recruiting
    Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07096869

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  18. Recruiting
    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07174336

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan

  19. Recruiting
    A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07244094

    Age 18 years to 95 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteChangchun, Hangzhou

  20. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  21. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  22. Recruiting
    Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06918262

    Age not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  23. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05646862

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan

  24. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  25. Recruiting
    Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-04
    Posted
    Registry
    NCT05744687

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesAnyang, Beijing, Changchun, Fuzhou, Guangzhou, Luoyang, Yinchuan

  26. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  27. Recruiting
    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05872347

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou

  28. Recruiting
    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05894239

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan

  29. Recruiting
    A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06064812

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  30. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  31. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  32. Recruiting
    JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05490472

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan

  33. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  34. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

  35. Recruiting
    Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-07
    Posted
    Registry
    NCT04136782

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang

  36. Recruiting
    Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
    Phase
    Not given
    Started
    2021-07
    Posted
    Registry
    NCT04476485

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang

  37. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

  38. Recruiting
    A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
    Phase
    Phase 1
    Started
    2013-01
    Posted
    Registry
    NCT02897700

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  39. Enrolling by invitation
    Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT06914661

    Age 18 years to 100 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  40. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Changchun

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Changchun, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital of Changchun University of Chinese Medicine长春中医药大学附属医院nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone6nonenonenone6nonenonenonenonenone3nonenonenonenonenonenonenonenone1nonenonenone1nonenonenonenonenonenonenonenonenonenone
China-Japan Union Hospital, Jilin University吉林大学白求恩第三医院(中日联谊医院)0none212231145122none00131104nonenonenone10nonenonenonenonenone3none22nonenone1542none0none1none10nonenonenone0none0nonenonenone11nonenonenonenonenonenonenonenonenone
First Hospital of Jilin University吉林大学第一医院35761 open417 open1121 open27772 open561 open13017072174 open024243 opennone021none11none142none202 open9252none1none201none03071 open1none0111nonenonenonenone0nonenonenonenone
Jilin Cancer Hospital吉林省肿瘤医院none04039none21nonenonenonenone0nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jilin Heart Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jilin Province FAW General Hospital吉林省一汽总医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jilin Province People's Hospital吉林省人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Hospital of Jilin University吉林大学第二医院0115173782010none1none111104nonenonenone6nonenonenonenonenonenone5nonenonenonenone123 open21none0none7none2nonenone1none107nonenonenone2nonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Changchun.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for breast cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Changchun on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data